Acknowledgments
We gratefully acknowledge the contribution of the Biobank of CEINGE. Work supported by grants from Regione Campania (Convenzione CEINGE-Regione Campania, DGRC 1901/2009), from IRCCS Fondazione SDN and from POR Campania FSE 2007-2013, Project CREME.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research support played no role in thestudy design; in the collection, analysis, and interpretationof data; in the writing of the report; or in the decision tosubmit the report for publication.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. National lipid association expert panel on familial hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol 2011;5:S9–17.10.1016/j.jacl.2011.03.452Search in Google Scholar PubMed
2. Bertolini S, Pisciotta L, Rabacchi C, Cefalù AB, Noto D, Fasano T, et al. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis 2013;227:342–8.10.1016/j.atherosclerosis.2013.01.007Search in Google Scholar PubMed
3. Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011;21:835–43.10.1016/j.numecd.2011.06.002Search in Google Scholar PubMed
4. Gentile M, Panico S, Jossa F, Mattiello A, Ubaldi S, Marotta G, et al. Small dense LDL particles and metabolic syndrome in a sample of middle-aged women. Findings from Progetto Clin Chim Acta 2008;388:179–83.10.1016/j.cca.2007.10.033Search in Google Scholar PubMed
5. Minhas R, Humphries SE, Qureshi N, Neil HA. Controversies in familial hypercholesterolaemia: recommendations of the NICE guideline development group for the identification and management of familial hypercholesterolaemia. Heart 2009;95:584–7.10.1136/hrt.2008.162909Search in Google Scholar PubMed
6. Romano M, Di Taranto MD, D’Agostino MN, Marotta G, Gentile M, Abate G, et al. Identification and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy. Atherosclerosis 2010;210:493–6.10.1016/j.atherosclerosis.2009.11.051Search in Google Scholar PubMed
7. Flanagan SE, Patch AM, Ellard S. Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. Genet Test Mol Biomarkers 2010;14:533–7.10.1089/gtmb.2010.0036Search in Google Scholar PubMed
8. Romano M, Di Taranto MD, Mirabelli P, D’Agostino MN, Iannuzzi A, Marotta G, et al. An improved method on stimulated T-lymphocytes to functionally characterize novel and known LDLR mutations. J Lipid Res 2011;52:2095–100.10.1194/jlr.D017772Search in Google Scholar PubMed PubMed Central
9. Wang Y, Huang Y, Hobbs HH, Cohen JC. Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res 2012;53:1932–43.10.1194/jlr.M028563Search in Google Scholar PubMed PubMed Central
10. Sun XM, Eden ER, Tosi I, Neuwirth CK, Wile D, Naoumova RP, et al. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet 2005;14: 1161–9.10.1093/hmg/ddi128Search in Google Scholar PubMed
11. Pullinger CR, Gaffney D, Gutierrez MM, Malloy MJ, Schumaker VN, Packard CJ, et al. The apolipoprotein B R3531C mutation: characteristics of 24 subjects from 9 kindreds. J Lipid Res 1999;40:318–27.10.1016/S0022-2275(20)33372-1Search in Google Scholar
©2014 by Walter de Gruyter Berlin/Boston
